Recent studies have also shown a trend for improved survival associated with higher Hb-levels due to rHu-EPO application in solid tumour patients receiving non-platinum based chemotherapy (Gabrilove et al, 2001; Littlewood et al, 2001).
Our results show for the first time that application of EPO caused activation of PARP proteins including PARP-1, and that polyADP-ribosylation subsequently mediated EPO-induced histone H4 acetylation and expression of c-fos and Egr-1 that mediate EPO-induced proliferation (Erickson-Miller et al, 2000).
Exogenous application of Epo not only protects retinal ganglion cells in a model of ischemia-reperfusion injury [ 19] but also photoreceptors in the model of light induced retinal degeneration [ 20, 21].
Erythropoietin (EPO) stimulates erythropoiesis through its specific receptor (EPO-R).
The present study was designed to determine the histological and ultrastructural changes in kidney cell of the rats after relatively long exhaustive exercise, evaluate the preventive and therapeutic effects of EPO on such a pathological conditions to provide empirical evidence for the application of EPO clinically.
STEM EPO activities should not be directed solely at the "rocket science" applications of technology and engineering capabilities.
In this work, we present experimental measurements of the thermal conductivity of a silver filled conductive epoxy (EPO-TEK H20E) which is widely used in cryogenic electronics applications.
Meanwhile, this technology has been exploited in various cell systems and for various applications including the establishment of viral producer cells [ 20, 21], EPO production [ 22], and for the evaluation of vector design [ 19] (see [ 17] for a recent review).
There is a disagreement whether chronic treatment with EPO is associated with activation of NO, which serves as a limiting factor to EPO-related hypertension (Kanagy et al., 2003) or, in the opposite view, chronic application of EPO results in depression of NO synthase and actually may cause hypertension (Wang and Vaziri, 1999).
For clinical applications where a transient effect would be adequate, such as myocardial infarction, the use of EPO-engineered universal donor allogeneic MSCs would be a substantial convenience.
